{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:07:10Z","timestamp":1788869230062,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"LEO Pharma A\/S"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jaad.2015.01.036","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T01:15:47Z","timestamp":1426036547000},"page":"816-821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Ingenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes"],"prefix":"10.1016","volume":"72","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Mark","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Erntoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. William","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.01.036_bib1","first-page":"1125","article-title":"Review of actinic keratosis, part I: etiology, epidemiology and clinical presentation","volume":"9","author":"Goldberg","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2015.01.036_bib2","first-page":"S45","article-title":"Actinic keratoses: past, present and future","volume":"9","author":"Fenske","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","article-title":"Guidelines for the management of actinic keratoses","volume":"156","author":"de Berker","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib4","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs topical tretinoin chemoprevention trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2015.01.036_bib5","first-page":"39","article-title":"Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer","volume":"3","author":"Cohen","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/0974-2077.94331","article-title":"Topical zinc sulphate (25%) solution: a new therapy for actinic keratosis","volume":"5","author":"Sharquie","year":"2012","journal-title":"J Cutan Aesthet Surg"},{"issue":"Suppl","key":"10.1016\/j.jaad.2015.01.036_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2133.2007.08268.x","article-title":"Management of field change in actinic keratosis","volume":"157","author":"Vatve","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/09546630601028737","article-title":"Management of actinic keratosis patients: a qualitative study","volume":"18","author":"Esmann","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2015.01.036_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-4632.2004.02056.x","article-title":"A prospective study of the use of cryosurgery for the treatment of actinic keratoses","volume":"43","author":"Thai","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","article-title":"Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness","volume":"107","author":"Chren","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/jdv.12090","article-title":"Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV taskforce on quality of life","volume":"27","author":"Prinsen","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.01.036_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1468-3083.2011.04005.x","article-title":"Open label randomized study comparing 3 months vs 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group","volume":"26","author":"Pflugfelder","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.01.036_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases","volume":"5","author":"Chren","year":"2001","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2015.01.036_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel\u00a0study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaad.2015.01.036_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2010.12.038","article-title":"Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response","volume":"66","author":"Rosen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib16","unstructured":"LEO Pharma A\/S. Picato (ingenol mebutate) gel, 0.015%,\u00a00.05%. Prescribing information. Available from: URL: www.picato.com\/_pdf\/PrescribingInformation.pdf. Accessed February 13, 2015."},{"key":"10.1016\/j.jaad.2015.01.036_bib17","unstructured":"LEO Pharma A\/S. Picato 150 micrograms\/gram gel. Summary of product characteristics. Available from: URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002275\/WC500135327.pdf. Accessed February 13, 2015."},{"key":"10.1016\/j.jaad.2015.01.036_bib18","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.jaad.2015.01.036_bib19","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jaad.2012.09.050","article-title":"Clinical findings using ingenol mebutate gel to treat actinic keratoses","volume":"68","author":"Martin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","article-title":"Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis","volume":"60","author":"Anderson","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2013.2766","article-title":"Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses","volume":"149","author":"Lebwohl","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1440-0960.2011.00785.x","article-title":"Field treatment of facial and scalp actinic keratoses with photodynamic therapy: survey of patient perceptions of treatment satisfaction and outcomes","volume":"52","author":"Tran","year":"2011","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib23","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/01.MLG.0000166177.98414.5E","article-title":"Creation of a quality of life instrument for nonmelanoma skin cancer patients","volume":"115","author":"Rhee","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaad.2015.01.036_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jaad.2009.02.022","article-title":"Quality of life in the actinic neoplasia syndrome: the VA topical tretinoin chemoprevention (VATTC) trial","volume":"61","author":"Weinstock","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.01.036_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2340\/00015555-0972","article-title":"Prospective quality of life impact of actinic keratoses: observations from the Veterans Affairs topical tretinoin chemoprevention trial","volume":"91","author":"Lee","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2015.01.036_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/09546634.2012.757285","article-title":"Patients' perceptions of topical treatments of actinic keratosis","volume":"25","author":"Esmann","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2015.01.036_bib27","first-page":"CD004415","article-title":"Interventions for actinic keratoses","volume":"12","author":"Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2015.01.036_bib28","first-page":"859","article-title":"A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis","volume":"50","author":"Carlin","year":"2004","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215001036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215001036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:33:42Z","timestamp":1759271622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215001036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0190962215001036"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.01.036","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ingenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.01.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}